MDxHealth price target lowered to $5 from $9 at Lake Street

Lake Street lowered the firm’s price target on MDxHealth (MDXH) to $5 from $9 and keeps a Buy rating on the shares. MDxHealth announced its Q1 results and the discontinuation of its Resolve UTI business following an unexplained policy reversal by Novitas, notes the analyst, who says the “headline is the strategic exit, not the print.” MDxHealth reset 2026 revenue guidance to to reflect the Resolve exit, adds the analyst, who remains confident in the future of the core prostate cancer business but realizes “management will be in the penalty box for a quarter or two as these changes are absorbed and performance is demonstrated.”